Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a biomarker for the effect of PTK787/ZK 222584 as second-line mono-therapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC).
conference contribution
posted on 2007-10-11, 17:12 authored by Mark A. Horsfield, Bruno Morgan, H. Krissel, Dirk LaurentDynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a biomarker for the effect of PTK787/ZK 222584 as second-line mono-therapy in patients with stage IIIB or stage IV non-small-cell lung cancer (NSCLC).
History
Citation
Annals of Oncology, 2006, 17(Supplement 9), p.ix219Published in
Annals of OncologyPublisher
Oxford University PressAvailable date
2007-10-11Notes
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Annals of Oncology following peer review. The definitive publisher-authenticated version [Annals of Oncology, 2006, 17(Supplement 9), abstract PD732] is available online at: http://annonc.oxfordjournals.org/. This is an abstract of a paper presented at the 31st ESMO Congress 29 September - 3 October, 2006: Istanbul, Turkey. The published versions lists additional authors.Language
enAdministrator link
Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC